Drug resistance missense mutations in cancer are subject to evolutionary constraints

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Friedman, Ran ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; BIOINFORMATICS; CANCER RESISTANCE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; GENE; HUMAN; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; SOMATIC MUTATION; AMINO ACID SUBSTITUTION; DRUG RESISTANCE; GENETICS; MOLECULAR EVOLUTION; NEOPLASM;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; FUSION PROTEINS, BCR-ABL; HUMANS; MUTATION, MISSENSE; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84893420223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082059     Document Type: Article

References (70)

1. Henkes M, van der Kuip H, Aulitzky WE (2008) Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec ®, Gleevec™). Ther Clin Risk Manag 4: 163-187. (Pubitemid 351460942)
2. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
3. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med 2.
4. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739.
5. Jänne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
6. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCRABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412.
7. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, et al. (2011) The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 71: 3189-3195.
8. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270. (Pubitemid 40943094)
9. Iwasa Y, Nowak MA, Michor F (2006) Evolution of resistance during clonal expansion. Genetics 172: 2557-2566.
10. Komarova NL, Wodarz D (2009) Combination therapies against chronic myeloid leukemia: shortterm versus long-term strategies. Cancer Res 69: 4904-4910.
11. Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, et al. (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 6: e27682.
12. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, et al. (2012) Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 72: 6362-6370.
13. Ohta T (1973) Slightly deleterious mutant substitutions in evolution. Nature 246: 96-98.
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
15. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
16. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311. (Pubitemid 39209661)
17. Ohashi K, Maruvka YE, Michor F, Pao W (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol.
18. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
19. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. (Pubitemid 47206930)
20. Chen Y, Takita J, Choi YL, Kato M, Ohira M, et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
21. George RE, Sanda T, Hanna M, Frohling S, Luther W, et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
22. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
23. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120-120.
24. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, et al. (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of european leukemianet. Blood 118: 1208-1215.
25. O'Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249. (Pubitemid 47523141)
26. Willis SG, Lange T, Demehri S, Otto S, Crossman L, et al. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106: 2128-2137. (Pubitemid 41291730)
27. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075. (Pubitemid 351439466)
28. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, et al. (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14: 7519-7525.
29. Marchler-Bauer A, Zheng C, Chitsaz F, Derbyshire MK, Geer LY, et al. (2013) CDD: conserved domains and protein three-dimensional structure. Nucleic Acids Res 41: 348-352.
30. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, et al. (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant cml: frequency and clonal relationships. Blood 121: 489-498.
31. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma dna. Sci Transl Med 4: 136-136.
32. Dutheil J (2008) Detecting site-specific biochemical constraints through substitution mapping. J Mol Evol 67: 257-265.
33. Nei M, Suzuki Y, Nozawa M (2010) The neutral theory of molecular evolution in the genomic era. Annu Rev Genomics Hum Genet 11: 265-289.
34. Pupko T, Bell RE, Mayrose I, Glaser F, Ben-Tal N (2002) Rate4Site: an algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues. Bioinformatics 18 Suppl 1: 71-77.
35. Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, et al. (2003) Consurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 19: 163-4. (Pubitemid 36150199)
36. Glaser F, Rosenberg Y, Kessel A, Pupko T, Ben-Tal N (2005) The ConSurf-HSSP database: the mapping of evolutionary conservation among homologs onto PDB structures. Proteins 58: 610-617. (Pubitemid 40176033)
37. Bashashati A, Haffari G, Ding J, Ha G, Lui K, et al. (2012) DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol 13: R124.
38. Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185: 862-864.
39. Ohta T, Tachida H (1990) Theoretical study of near neutrality. i. heterozygosity and rate of mutant substitution. Genetics 126: 219-229. (Pubitemid 20336287)
40. Berge EM, Aisner DL, Doebele RC (2013) Erlotinib response in an nsclc patient with a novel compound g719d+l861r mutation in egfr. J Thorac Oncol 8: 83-84.
41. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, et al. (2013) Compound egfr mutations and response to egfr tyrosine kinase inhibitors. J Thorac Oncol 8: 45-51.
42. De Grassi A, Segala C, Iannelli F, Volorio S, Bertario L, et al. (2010) Ultradeep sequencing of a human ultraconserved region reveals somatic and constitutional genomic instability. PLoS Biol 8: e1000275.
43. D'Antonio M, Pendino V, Sinha S, Ciccarelli FD (2012) Network of cancer genes (ncg 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res 40: 978-983.
44. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
45. Martins FC, De S, Almendro V, Gönen M, Park SY, et al. (2012) Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2: 503-511.
46. Podlaha O, Riester M, De S, Michor F (2012) Evolution of the cancer genome. Trends Genet 28: 155-163.
47. Foo J, Leder K, Mumenthaler SM (2013) Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl 6: 54-69.
48. Kaminker JS, Zhang Y, Watanabe C, Zhang Z (2007) CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res 35: 595-598.
49. Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68: 1675-1682. (Pubitemid 351416551)
50. Wong WC, Kim D, Carter H, Diekhans M, Ryan MC, et al. (2011) CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer. Bioinformatics 27: 2147-2148.
51. Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N (2012) Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med 4: 89-89.
52. Goymer P (2008) Natural selection: The evolution of cancer. Nature 454: 1046-1048.
53. Fillon M (2012) Cancer and natural selection. J Natl Cancer Inst 104: 1773-1774.
54. Gatenby R (2012) Perspective: Finding cancer's first principles. Nature 491.
55. Gillies RJ, Verduzco D, Gatenby RA (2012) Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12: 487-493.
56. Aktipis CA, Nesse RM (2013) Evolutionary foundations for cancer biology. Evol Appl 6: 144-159.
57. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA (2013) Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A 110: 2910-2915.
58. Nunney L (2013) The real war on cancer: the evolutionary dynamics of cancer suppression. Evol Appl 6: 11-19.
59. Boratyn GM, Schäffer AA, Agarwala R, Altschul SF, Lipman DJ, et al. (2012) Domain enhanced lookup time accelerated BLAST. Biol Direct 7: 12-12.
60. Bairoch A, Apweiler R (2000) The swiss-prot protein sequence database and its supplement trembl in 2000. Nucleic Acids Res 28: 45-48. (Pubitemid 30047711)
61. Rice P, Longden I, Bleasby A (2000) EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16: 276-277.
62. Needleman SB, Wunsch CD (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 48: 443-453.
63. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30: 3059-3066. (Pubitemid 34851225)
64. Penn O, Privman E, Landan G, Graur D, Pupko T (2010) An alignment confidence score capturing robustness to guide tree uncertainty. Mol Biol Evol 27: 1759-1767.
65. Biegert A, Söding J (2009) Sequence context-specific profiles for homology searching. Proc Natl Acad Sci U S A 106: 3770-3775.
66. Angermüller C, Biegert A, Söding J (2012) Discriminative modelling of context-specific amino acid substitution probabilities. Bioinformatics 28: 3240-3247.
67. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38. (Pubitemid 26152973)
68. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, et al. (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343: 342-350.
69. Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, et al. (2012) The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem 55: 6523-6540.
70. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141. (Pubitemid 40248339)